# US 2008/0306270 A1 · Process for the Preparation of a Leukotriene Antagonist and Intermediates Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306270 A1
- Document ID: US20080306270A1
- Status: Published application
- Kind: A1
- Application number: 12/092,554
- Filed: 2006-11-03
- Published: 2008-12-11
- Earliest claimed: 2005-11-04
- Assignees: Esteve Quimica, S.A.
- Inventors: Laura Coppi; Marti Bartra Sanmarti; Yolanda Gasanz Guillen; Montserrat Monsalvatje Llagostera; Pedro Talavera Escasany
- Web page: https://patentgrep.com/patent/US20080306270A1

## CPC

- C07D 215/18: Halogen atoms or nitro radicals
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It comprises a preparation process of Montelukast from a new intermediate compound of formula (VI), which is previously prepared by reaction of the corresponding sulfonate with 1-(mercaptomethyl)cyclopropyl)methanol. Compound (VI) is reacted with a Grignard reactant to convert the ester group into a tertiary alcohol, followed by conversion of the primary alcohol into a sulfonate, substitution of the sulfonate group by a cyano group, and finally transforming the cyano compound to the carboxilic acid compound by a hydrolysis reaction to afford Montelukast. Montelukast can also be prepared by a hydrolysis reaction of the corresponding amide. It also comprises new intermediate compounds useful in such preparation process.

## Claims

### Claim 1

A process for the preparation of Montelukast (I), or a pharmaceutically acceptable salt, or a solvate thereof, including a hydrate,
the process comprising the steps of:
(a) reacting a compound of formula (IV), wherein R1 is a radical selected from the group consisting of (C1-C4)-alkyl, phenyl, and phenyl mono- or disubstituted by a (C1-C4)-alkyl radical, with an alkaline metal cyanide, to give a compound of formula (III) and isolating said compound (III) as free base or as a salt thereof;
(b) optionally, hydrolysing the compound of formula (III) obtained in step (a) in reaction conditions that lead to a compound of formula (II) and isolating said compound (II) from the reaction medium;
(c) submitting the compound obtained in step (a) or in step (b) to a hydrolysis reaction in reaction conditions that lead to Montelukast (I); and
(d) optionally treating Montelukast (I) with a pharmaceutically acceptable base to form the corresponding salt.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the compound of formula (III) is isolated as free base.

### Claim 3 (depends on 1, 2)

The process according to any of claims 1 or 2, wherein R1 is selected from the group consisting of methyl, phenyl, and 4-methyl phenyl.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The process according to claim 1, wherein step (a) is carried out in the presence of a phase transfer catalyst.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The process according to claim 1, wherein the hydrolysis reaction of one or both of steps (b) and (c) is carried out with a base.

### Claim 10

(canceled)

### Claim 11 (depends on 9)

The process according to claim 9, wherein the hydrolysis is carried out into a mixture comprising water and an organic solvent, optionally in the presence of a phase transfer catalyst.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The process according to claim 1, comprising the further step of reacting a compound of formula (V) with a sulphonyl chloride of formula Cl—SO2—R1, wherein R1 has the same meaning as in claim 1, to give a compound of formula (IV)

### Claim 14 (depends on 13)

The process according to claim 13, comprising the further step of reacting a compound of formula (VI) with a Grignard reagent selected from methyl lithium and a methyl magnesium halide, optionally in the presence of cerium chloride, to give a compound of formula (V), and said compound (V) is isolated as free base or as a salt thereof

### Claim 15 (depends on 14)

The process according to claim 14, wherein the compound of formula (V) is isolated as free base.

### Claim 16

(canceled)

### Claim 17 (depends on 14)

The process according to claim 14, comprising the further step of reacting the compound of formula (VII), wherein R2 is a radical selected from the group consisting of (C1-C4)-alkyl, phenyl, and phenyl mono- or disubstituted by (C1-C4)-alkyl radicals, with a compound of formula (VIII), in the presence of a base to give a compound of formula (VI), and said compound (VI) is isolated as free base or as a salt thereof

### Claim 18 (depends on 17)

The process according to claim 17, wherein the compound of formula (VI) is isolated as free base.

### Claim 19 (depends on 17)

The process according to claim 17, wherein the compound (VI) is isolated as an oxalate salt.

### Claim 20 (depends on 17)

The process according to claim 17, wherein R2 is selected from the group consisting of methyl, phenyl, and 4-methyl phenyl.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

A compound of formula (IV), wherein R1 is a radical selected from the group consisting of (C1-C4)-alkyl, phenyl, and phenyl mono- or disubstituted by a (C1-C4)-alkyl radical

### Claim 25 (depends on 24)

A compound according to claim 24, wherein R1 is selected from methyl, phenyl, and 4-methylphenyl.

### Claim 26

(canceled)

### Claim 27

A compound of formula (V), or a salt thereof

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The compound according to claim 27, wherein the salt is a citrate.

### Claim 30

A compound of formula (VI), or a salt thereof

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The compound according to claim 30, wherein the salt is an oxalate.

### Claim 33

A salt of the compound of formula (III) which is selected from the group consisting of oxalate, L-(−)-malate, L-(−)-tartrate, maleate, fumarate, succinate, benzoate, 4-hydroxymandelate, citrate, benzenesulfonate, and mandelate
